Grindeks ir Baltijas valstu vado\u0161ais farm\u0101cijas uz\u0146\u0113mums, kas ir sasniedzis koncerna l\u012bme\u0146a att\u012bst\u012bbas stadiju, kur\u0101 strat\u0113\u0123iski p\u0101rdom\u0101ta dom\u0101\u0161ana un noz\u012bm\u012bgu l\u0113mumu pie\u0146em\u0161ana ir k\u013cuvusi par uz\u0146\u0113muma ikdienu. Uz\u0146\u0113mums turpina palielin\u0101t koncerna konkur\u0113tsp\u0113ju Eiropas un pasaules tirgos, k\u0101 ar\u012b sasniedz ambiciozus m\u0113r\u0137us ar re\u0101liem rezult\u0101tiem.<\/p>\n\n\n\n
Grindeks meitas uz\u0146\u0113mums AS Kalceks, kas specializ\u0113jas uz slimn\u012bcu segmenta medikamentiem, \u0161\u012b gada j\u016bnij\u0101 ir veiksm\u012bgi nosl\u0113dzis pirm\u0101 produkta re\u0123istr\u0101ciju \u0136\u012bn\u0101. Re\u0123istr\u0101cijas apliec\u012bba ir sa\u0146emta produktam, kura farmakoterapeitisk\u0101 grupa ir perif\u0113riskas darb\u012bbas miorelaksanti. Tas tiek izmantots k\u0101 vid\u0113ji ilgas darb\u012bbas nedepolariz\u0113jo\u0161ais benzilizohinol\u012bna grupas skeleta muskulat\u016bras relaksants intravenozai ievad\u012b\u0161anai. Produkts ir indic\u0113ts lieto\u0161anai \u0137irur\u0123isku un citu proced\u016bru laik\u0101 pieaugu\u0161ajiem un b\u0113rniem no 1 m\u0113ne\u0161a vecuma.<\/p>\n\n\n\n
\n<\/p>\nGrindeks padomes priek\u0161s\u0113d\u0113t\u0101js Kirovs Lipmans:<\/strong> \u201c Re\u0123istr\u0101cijas process \u0136\u012bn\u0101 ir laikietilp\u012bgs un sare\u017e\u0123\u012bts process, kas ilga gandr\u012bz tr\u012bs gadus. Neskatoties uz da\u017e\u0101diem pand\u0113mijas un \u0123eopolitiski rad\u012btiem \u0161\u0137\u0113r\u0161\u013ciem, jau p\u0113rn Grindeks koncerna meitas uz\u0146\u0113mumi galveno uzman\u012bbu piev\u0113rsa jauniem produktiem un glob\u0101lai ekspansijai. Esmu patiesi gandar\u012bts par Grindeks koncerna sasniegumiem un lepojos, ka Baltijas l\u012bmen\u012b esam viens no pirmajiem farm\u0101cijas uz\u0146\u0113mumiem, kur\u0161 re\u0123istr\u0113jis \u0123en\u0113risko medikamentu \u0136\u012bn\u0101. M\u016bsu komandas darba rezult\u0101ti skaidri apliecina uz\u0146\u0113muma konkur\u0113tsp\u0113ju pasaules ar\u0113n\u0101.\u201d<\/cite><\/blockquote>\n\n\n\n
Grindeks uzskata, ka tam ir milz\u012bgs potenci\u0101ls palielin\u0101t pacientu piek\u013cuvi kvalitat\u012bv\u0101m un efekt\u012bv\u0101m z\u0101l\u0113m \u0101rstniec\u012bb\u0101 svar\u012bg\u0101s terapeitiskaj\u0101s grup\u0101s \u2013 CNS, sirds un asinsvadu, diab\u0113ta un onkolo\u0123isko slim\u012bbu \u0101rst\u0113\u0161anai. Turkl\u0101t Grindeks meitasuz\u0146\u0113mums Kalceks sevi ir p\u0101rliecino\u0161i pieteicis glob\u0101l\u0101 konkurenc\u0113 slimn\u012bcu segment\u0101. J\u016bnij\u0101 Grindeks re\u0123istr\u0113t\u0101 medikamenta tirdzniec\u012bbas uzs\u0101k\u0161ana \u0136\u012bn\u0101 pl\u0101nota jau \u0161\u012b gada beig\u0101s. Tas uz\u0146\u0113mumam paver jaunas izaugsmes iesp\u0113jas \u0100zijas re\u0123ion\u0101, uz\u0146\u0113muma vad\u012bbai uzsverot, ka \u0161obr\u012bd \u0136\u012bn\u0101 notiek v\u0113l 3 Grindeks koncerna produktu re\u0123istr\u0101cijas process, kuru re\u0123istr\u0101cijas apliec\u012bbas sa\u0146em\u0161ana pl\u0101nota uz n\u0101kam\u0101 gada s\u0101kumu.<\/p>\n\n\n\n
Koncerns p\u0113d\u0113jos gados strauji aug un ir p\u0101rliecin\u0101ts, ka at\u0161\u0137ir\u012bb\u0101 no pasaules farm\u0101cijas tirgus l\u012bderiem, tas sp\u0113j \u0101tri un elast\u012bgi rea\u0123\u0113t uz pacientu vajadz\u012bb\u0101m un piepras\u012bjumu.<\/p>\n","protected":false},"excerpt":{"rendered":"
Grindeks ir Baltijas valstu vado\u0161ais farm\u0101cijas uz\u0146\u0113mums, kas ir sasniedzis koncerna l\u012bme\u0146a att\u012bst\u012bbas stadiju, kur\u0101 strat\u0113\u0123iski p\u0101rdom\u0101ta dom\u0101\u0161ana un noz\u012bm\u012bgu l\u0113mumu pie\u0146em\u0161ana ir k\u013cuvusi par…<\/p>\n","protected":false},"author":6,"featured_media":10133,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-10132","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-3"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/10132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=10132"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/10132\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/10133"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=10132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=10132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=10132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}